Parabolic Drugs Ltd. | Income Statement
Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
4,301
2,284
760
740
732
Cost of Goods Sold (COGS) incl. D&A
4,847
3,712
4,223
1,689
1,078
Gross Income
546
1,428
3,464
949
347
SG&A Expense
1,030
120
74
49
165
EBIT
1,586
1,553
3,541
998
512
Non Operating Income/Expense
180
33
198
52
42
Interest Expense
837
990
1,076
108
84
Pretax Income
2,221
2,502
4,813
1,050
554
Income Tax
883
1,303
44
31
18
Consolidated Net Income
1,338
3,805
4,857
1,081
571
Net Income
1,338
3,805
4,857
1,081
571
Net Income After Extraordinaries
1,338
3,805
4,857
1,081
571
Net Income Available to Common
1,338
3,805
4,857
1,081
571
EPS (Basic)
21.62
61.47
78.48
17.46
9.30
Basic Shares Outstanding
62
62
62
62
-
EPS (Diluted)
21.62
61.47
78.48
17.46
-
Diluted Shares Outstanding
62
62
62
62
-
EBITDA
904
821
2,869
461
166
Other Operating Expense
10
5
3
-
-
Non-Operating Interest Income
23
9
2
4
-
About Parabolic Drugs
View Profile
